This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alexza Pharma: FDA Panel Live Blog

BETHESDA, Md. ( TheStreet) -- Alexza Pharmaceuticals (ALXA - Get Report) is trying to convince an independent expert panel Monday that safety concerns focused on the risk of asthma-like side effects should not prevent the approval of its inhaled antipsychotic drug Adasuve.

Adasuve is a small, handheld device that delivers an inhaled dose of the antipsychotic drug loxapine into the lungs of patients. Adasuve is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.

The U.S. Food and Drug Administration rejected Alexza's Adasuve application in October 2010 primarily due to concerns that inhaling the drug caused bronchospasms, or asthma-like constrictions of the lungs, in some patients.

Alexza resubmitted Adasuve to FDA, which asked an advisory panel of independent experts to review the drug/device Monday. The panel will be voting on whether or not to recommend Adasuve's approval.

In its morning presentation, Alexza argued that Adasuve is effective in treating acute episodes of agitation in schizophrenia patients. The company believes using an inhaled antipsychotic could be a meaningful benefit for agitated patients who typically must be physically restrained and treated with injections.

Alexza proposed a risk management plan that would screen out patients with lung problems and monitor patients treated with Adasuve to manage any bronchospasms, if they occur.

FDA used its presentation time at Monday's panel to raise questions about the way Alexza studies Adasuve in its clinical trials. The agency's reviewers said patients in the Adasuve studies were carefully screened which means they may have been better suited for Adasuve than "real world" schizophrenia patients. The FDA also presented data highlighting the lung safety concerns attributable to Adasuve.

The expert panel will spend the bulk of the afternoon debating the safety of Adasuve and will ultimately vote on whether to recommend approval or not.

Alexza shares were halted for trading Monday at 62 cents. The stock fell sharply last Thursday after FDA released its Adasuve review.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ALXA $2.05 0.00%
AAPL $127.60 0.00%
FB $83.09 0.00%
GOOG $535.38 0.00%
TSLA $205.27 0.00%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs